Dr. Lauren Elizabeth Eisenbud, MD

Dr. Eisenbud practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Eisenbud's NPI, 1245650563, was assigned on April 25, 2014. Dr. Eisenbud graduated from St. George's University School of Medicine in 2014. Dr. Eisenbud holds California license A144434.

Dr. Eisenbud's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (626) 256-4673.

Dr. Eisenbud's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. Dr. Eisenbud is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is City of Hope. Dmand AI also links Dr. Eisenbud to 4 more hospitals, 2 group practices and clinics, 2 medical groups and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Eisenbud practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Eisenbud's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Eisenbud is board certified in hematology by the American Board of Internal Medicine. Dr. Eisenbud is licensed in California.

Dmand AI lists breast cancer, chronic anemia, colorectal cancer, lung cancer, lymphoma, neutropenia and purpura and thrombocytopenia among the conditions Dr. Eisenbud treats.

CMS data shows 55,180 Medicare services from Dr. Eisenbud across 35 procedure codes in 2024, for 544 Medicare patients. Medicare paid $839,061 for them.

CMS counts 544 Medicare patients who saw Dr. Eisenbud in 2024. The largest group is 75 to 84, with 231 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 4% are also on Medicaid. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Eisenbud's median patient age at 67, with 72% women.

In 2024, Dr. Eisenbud wrote 516 Medicare Part D claims for 138 patients. 74% of them were for generic drugs. CMS names the drug for 330 of them, across 16 drugs with 11 or more claims each, at $520,037 in total drug cost. In 2023, CMS named 277 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Eisenbud for performance year 2024, reported as part of a group. Dr. Eisenbud accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Eisenbud as offering telehealth.

Dmand AI links 9 papers to Dr. Eisenbud, published from 2012 to 2020. 2012 was the busiest year, with 2. The most frequent topics are Breast Neoplasms, Comparative Genomic Hybridization and Flow Cytometry. Dr. Eisenbud has published most often in Cancer Res. Dr. Eisenbud's most frequent co-authors are Michelle Elizabeth Melisko, MD, John W. Park, MD and Nataliya Mar, MD.

CMS Open Payments shows 42 general payments to Dr. Eisenbud from 19 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 80% of the total. Genentech, Inc. paid the most, $382.

Dr. Eisenbud graduated from St. George's University School of Medicine in 2014.

Dr. Eisenbud is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.